{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:57:28Z","timestamp":1772240248330,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.bulcan.2015.11.008","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T14:03:03Z","timestamp":1452520983000},"page":"180-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Recommandations 2015\u00a0du France Intergroupe des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques pour la gestion du risque d\u2019\u00e9v\u00e9nements cardiovasculaires sous nilotinib au cours de la leuc\u00e9mie my\u00e9lo\u00efde chronique"],"prefix":"10.1016","volume":"103","author":[{"given":"Delphine","family":"Rea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5603-3333","authenticated-orcid":false,"given":"Shanti","family":"Ame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Charbonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0776-4615","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Coiteux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Cony-Makhoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Escoffre-Barbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3687-0932","authenticated-orcid":false,"given":"Martine","family":"Gardembas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Guerci-Bresler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Legros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Tulliez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Hermet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyacinthe","family":"Johnson-Ansah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Lapusan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Quittet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Messas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bulcan.2015.11.008_bib0290","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.bulcan.2015.11.008_bib0295","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2015.11.008_bib0300","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bulcan.2015.11.008_bib0305","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2\u00a0trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.bulcan.2015.11.008_bib0310","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.bulcan.2015.11.008_bib0315","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bulcan.2015.11.008_bib0320","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","article-title":"Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry","volume":"122","author":"H\u00f6glund","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2015.11.008_bib0325","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s10552-009-9417-9","article-title":"Trends in adult leukemia incidence and survival in Denmark, 1943\u20132003","volume":"20","author":"Thygesen","year":"2009","journal-title":"Cancer Causes Control"},{"issue":"7","key":"10.1016\/j.bulcan.2015.11.008_bib0330","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","article-title":"Trends in chronic myeloid leukemia incidence and survival in the United States from 1975\u00a0to 2009","volume":"54","author":"Chen","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.bulcan.2015.11.008_bib0335","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2015.11.008_bib0340","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2015.11.008_bib0345","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2015.11.008_bib0350","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00277-015-2318-y","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"94","author":"Rea","year":"2015","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.bulcan.2015.11.008_bib0355","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1\u00a0kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.bulcan.2015.11.008_bib0360","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bulcan.2015.11.008_bib0365","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2015.11.008_bib0370","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2015.11.008_bib0375","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.bulcan.2015.11.008_bib0380","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.bulcan.2015.11.008_bib0385","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood.V122.21.92.92","article-title":"ENESTnd Update: nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and sokal risk at diagnosis on long-term outcomes","volume":"122","author":"Saglio","year":"2013","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bulcan.2015.11.008_bib0390","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood.V124.21.4541.4541","article-title":"Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term follow-up (f\/u) of ENESTnd","volume":"124","author":"Larson","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2015.11.008_bib0395","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2013-12-544015","article-title":"Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib","volume":"124","author":"Hughes","year":"2014","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.bulcan.2015.11.008_bib0400","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bulcan.2015.11.008_bib0405","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bulcan.2015.11.008_bib0410","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2015.11.008_bib0415","first-page":"997","article-title":"Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group)","volume":"97","author":"Etienne","year":"2010","journal-title":"Bull Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2015.11.008_bib0420","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3109\/02841861003691952","article-title":"Fatal myocardial infarction during nilotinib treatment in a 60-year-old male patient","volume":"49","author":"Brauchli","year":"2010","journal-title":"Acta Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2015.11.008_bib0425","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.bulcan.2015.11.008_bib0430","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ajh.22051","article-title":"Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia","volume":"86","author":"Tefferi","year":"2011","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.bulcan.2015.11.008_bib0435","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.bulcan.2015.11.008_bib0440","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.bulcan.2015.11.008_bib0445","first-page":"1","article-title":"Bilateral renal artery stenosis in a patient with chronic myeloid leukemia treated with nilotinib","volume":"1","author":"Kristensen","year":"2012","journal-title":"Leuk Res Rep"},{"issue":"2","key":"10.1016\/j.bulcan.2015.11.008_bib0450","first-page":"113","article-title":"Cerebrovascular events during nilotinib treatment","volume":"72","author":"Jager","year":"2014","journal-title":"Neth J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2015.11.008_bib0455","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jmv.2015.05.006","article-title":"Peripheral artery occlusive disease of the lower limbs: rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia","volume":"40","author":"Gautier","year":"2015","journal-title":"J Mal Vasc"},{"issue":"13","key":"10.1016\/j.bulcan.2015.11.008_bib0460","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"issue":"39","key":"10.1016\/j.bulcan.2015.11.008_bib0465","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1093\/eurheartj\/eht356","article-title":"Cardiovascular disease in Europe: epidemiological update","volume":"34","author":"Nichols","year":"2013","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.bulcan.2015.11.008_bib0470","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bulcan.2015.11.008_bib0475","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ejh.12096","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study","volume":"90","author":"Levato","year":"2013","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.bulcan.2015.11.008_bib0480","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bulcan.2015.11.008_bib0485","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/leu.2014.342","article-title":"Usefulness of the 2012\u00a0European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia","volume":"29","author":"Rea","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bulcan.2015.11.008_bib0490","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/fcp.12102","article-title":"Are nilotinib-associated vascular adverse events an under-estimated problem?","volume":"29","author":"St\u00e8ve-Dumont","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"issue":"14","key":"10.1016\/j.bulcan.2015.11.008_bib0495","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jacc.2009.07.020","article-title":"Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians","volume":"54","author":"Cooney","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.bulcan.2015.11.008_bib0500","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00277-014-2231-9","article-title":"Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment","volume":"94","author":"Breccia","year":"2015","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.bulcan.2015.11.008_bib0505","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jmv.2014.07.046","article-title":"Pr\u00e9valence des maladies cardiovasculaires chez 42\u00a0patients trait\u00e9s par Nilotinib pour une leuc\u00e9mie my\u00e9lo\u00efde chronique","volume":"39","author":"Morange","year":"2014","journal-title":"J Mal Vasc"},{"issue":"15S","key":"10.1016\/j.bulcan.2015.11.008_bib0510","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1200\/jco.2015.33.15_suppl.7045","article-title":"Impact of nilotinib treatment on subclinical cardiovascular biomarkers","volume":"33","author":"Gardembas","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2015.11.008_bib0515","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/ejh.12367","article-title":"Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome","volume":"94","author":"Mirault","year":"2015","journal-title":"Eur J Haematol"},{"issue":"21","key":"10.1016\/j.bulcan.2015.11.008_bib0520","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood.V124.21.1800.1800","article-title":"Further evaluation of pro-atherogenic and anti-angiogenic effects of nilotinib in mice and in patients with Ph-chromosome+ CML","volume":"124","author":"Hadzijusufovic","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bulcan.2015.11.008_bib0525","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.3324\/haematol.2013.086355","article-title":"Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia","volume":"98","author":"Racil","year":"2013","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bulcan.2015.11.008_bib0530","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia","volume":"99","author":"Rea","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.bulcan.2015.11.008_bib0540","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jacc.2009.09.081","article-title":"Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we?","volume":"56","author":"Shah","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.bulcan.2015.11.008_bib0545","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1517\/17425255.2015.1056149","article-title":"Drug-drug interactions that interfere with statin metabolism","volume":"11","author":"Hirota","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"25","key":"10.1016\/j.bulcan.2015.11.008_bib0550","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"7655","key":"10.1016\/j.bulcan.2015.11.008_bib0555","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/bmj.39554.624086.AD","article-title":"Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance","volume":"336","author":"Cooper","year":"2008","journal-title":"BMJ"},{"issue":"Suppl 2","key":"10.1016\/j.bulcan.2015.11.008_bib0560","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","article-title":"A review of the European LeukemiaNet recommendations for the management of CML","volume":"94","author":"Baccarani","year":"2015","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.bulcan.2015.11.008_bib0565","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ajh.23442","article-title":"Nilotinib treatment-associated cerebrovascular disease and stroke","volume":"88","author":"Coon","year":"2013","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.bulcan.2015.11.008_bib0285","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1038\/bcj.2014.66","article-title":"Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion","volume":"4","author":"Maurizot","year":"2014","journal-title":"Blood Cancer J"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115003689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115003689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T20:44:03Z","timestamp":1600029843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115003689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0007455115003689"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2015.11.008","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommandations 2015\u00a0du France Intergroupe des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques pour la gestion du risque d\u2019\u00e9v\u00e9nements cardiovasculaires sous nilotinib au cours de la leuc\u00e9mie my\u00e9lo\u00efde chronique","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2015.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}